Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus-eluting coronary stent - Svelte Medical Systems

Next Previous
Drug Profile

Sirolimus-eluting coronary stent - Svelte Medical Systems

Alternative Names: Drug-eluting coronary stent - Svelte

Latest Information Update: 30 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Svelte Medical Systems
  • Class 3-ring heterocyclic compounds; Alcohols; Alkenes; Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Aza compounds; Cardiovascular therapies; Cyclic ethers; Cyclohexanols; Esters; Eye disorder therapies; Ketones; Lactones; Macrocyclic compounds; Macrolides; Methyl ethers; Nootropics; Piperidines; Polyenes; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ischaemic heart disorders

Most Recent Events

  • 31 May 2019 Svelte completes the phase II DIRECT II trial in Ischaemic heart disorders in Belgium, Czech Republic, France, Germany Netherlands, Sweden and Switzerland (Intracoronary) (NCT01788150)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ischaemic-heart-disorders in New Zealand (Intracoronary, Implant)
  • 19 Jan 2016 Launched for Ischaemic heart disorders in European Union (Intracoronary)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top